Molecular network of the comprehensive multiple sclerosis brain-lesion proteome

Background A recent proteomics study of multiple sclerosis (MS) lesion-specific proteome profiling clearly revealed a pivotal role of coagulation cascade proteins in chronic active demyelination. However, among thousands of proteins examined, nearly all of remaining proteins are yet to be characterized in terms of their implications in MS brain-lesion development. Methods By the systems biology approach using four different pathway analysis tools of bioinformatics, we studied molecular networks and pathways of the proteome dataset of acute plaques, chronic active plaques (CAP), and chronic plaques (CP). Results The database search on Kyoto Encyclopedia of Genes and Genomes (KEGG) and protein analysis through evolutionary relationships (PANTHER) indicated the relevance of extracellular matrix (ECM)–mediated focal adhesion and integrin signaling to CAP and CP proteome. KeyMolnet disclosed a central role of the complex interaction among diverse cytokine signaling pathways in brain-lesion development at all disease stages, as well as a role of integrin signaling in CAP and CP. Ingenuity pathway analysis (IPA) identified the network constructed with a wide range of ECM components, such as collagen, type I α1, type I α2, type VI α2, type VI α3, fibronectin 1, fibulin 2, laminin α1, vitronectin, and heparan sulfate proteoglycan, as one of the networks highly relevant to CAP proteome. Conclusions Although four distinct platforms produced diverse results, they commonly suggested a role of ECM and integrin signaling in development of chronic lesions of MS. These in silico observations indicate that the selective blockade of the interaction between ECM and integrins in brain lesions in situ would be a target for therapeutic intervention in MS.

[1]  Massimo Marchiori,et al.  Error and attacktolerance of complex network s , 2004 .

[2]  D. Sheppard,et al.  Distinct roles for astrocyte αvβ5 and αvβ8 integrins in adhesion and migration , 1999 .

[3]  L. Steinman,et al.  Transcriptional analysis of targets in multiple sclerosis , 2003, Nature Reviews Immunology.

[4]  Sonali Patil,et al.  Getting Started in Biological Pathway Construction and Analysis , 2008, PLoS Comput. Biol..

[5]  J. Sepulcre,et al.  A Network Analysis of the Human T-Cell Activation Gene Network Identifies Jagged1 as a Therapeutic Target for Autoimmune Diseases , 2007, PloS one.

[6]  A. Itai,et al.  New approaches to mechanism analysis for drug discovery using DNA microarray data combined with KeyMolnet. , 2005, Current drug discovery technologies.

[7]  R. Sherwin,et al.  Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression. , 2004, Molecular cancer therapeutics.

[8]  M. Chen,et al.  Vitronectin and Integrin Vitronectin Receptor Localization in Multiple Sclerosis Lesions , 1995, Journal of neuropathology and experimental neurology.

[9]  M. Ginsberg,et al.  Integrin‐associated proteins as potential therapeutic targets , 2008, Immunological reviews.

[10]  Jorge R. Oksenberg,et al.  Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis , 2002, Nature Medicine.

[11]  D. Hoekstra,et al.  Fibronectin impedes “myelin” sheet-directed flow in oligodendrocytes: A role for a beta 1 integrin-mediated PKC signaling pathway in vesicular trafficking , 2006, Molecular and Cellular Neuroscience.

[12]  G. D. del Zoppo,et al.  Fibronectin- and Vitronectin-Induced Microglial Activation and Matrix Metalloproteinase-9 Expression Is Mediated by Integrins α5β1 and αvβ51 , 2007, The Journal of Immunology.

[13]  J. Savill,et al.  Proinflammatory cytokines potentiate thrombospondin-mediated phagocytosis of neutrophils undergoing apoptosis. , 1995, Journal of immunology.

[14]  S. McQuaid,et al.  Absence of aquaporin-4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal-appearing white matter , 2007, Acta Neuropathologica.

[15]  Nan Guo,et al.  PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways , 2006, Nucleic Acids Res..

[16]  A. Minagar,et al.  Elevated plasma endothelial microparticles in multiple sclerosis , 2001, Neurology.

[17]  L. Steinman Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab , 2005, Nature Reviews Drug Discovery.

[18]  Hans Lassmann,et al.  The Immunopathology of Multiple Sclerosis: An Overview , 2007, Brain pathology.

[19]  C. Carman,et al.  Structural basis of integrin regulation and signaling. , 2007, Annual review of immunology.

[20]  B. Ganter,et al.  Emerging applications of network and pathway analysis in drug discovery and development. , 2008, Current opinion in drug discovery & development.

[21]  W. Yung,et al.  Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo , 2007, Molecular Cancer Therapeutics.

[22]  D. Sheppard,et al.  Distinct roles for astrocyte alphavbeta5 and alphavbeta8 integrins in adhesion and migration. , 1999, Journal of cell science.

[23]  Sergio E. Baranzini,et al.  Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets , 2008, Nature.

[24]  Yoshihiro Yamanishi,et al.  KEGG for linking genomes to life and the environment , 2007, Nucleic Acids Res..

[25]  Helga E de Vries,et al.  The extracellular matrix in multiple sclerosis pathology , 2007, Journal of neurochemistry.

[26]  C. Polman,et al.  Elevated osteopontin levels in active relapsing‐remitting multiple sclerosis , 2003, Annals of neurology.

[27]  Bernhard Hemmer,et al.  Treatment and treatment trials in multiple sclerosis , 2007, Current opinion in neurology.

[28]  J. Satoh,et al.  Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis , 2005, Neurobiology of Disease.

[29]  R. Sobel,et al.  Fibronectin in multiple sclerosis lesions. , 1989, The American journal of pathology.

[30]  R. Sobel The Extracellular Matrix in Multiple Sclerosis Lesions , 1998, Journal of neuropathology and experimental neurology.

[31]  H. Weiner,et al.  Systems biology approaches for the study of multiple sclerosis , 2008, Journal of cellular and molecular medicine.

[32]  S. Kingsmore,et al.  Genome-wide association studies: progress and potential for drug discovery and development , 2008, Nature Reviews Drug Discovery.